Shamburg News · 8-K filed Nov 5, 2026, 7:13 AM EST

Akebia Therapeutics Reports Third Quarter 2026 Results; Net Loss of $14.4 Million

AKBA · Akebia Therapeutics, Inc.

  • Earnings
  • Materiality: high

Akebia Therapeutics reported a net loss of $14.4 million for the third quarter ended September 30, 2026, compared with net income of $0.5 million a year earlier. Total revenues were $36.9 million versus $58.8 million, with Vafseo net product revenues of $14.8 million and Auryxia net product revenues of $20.0 million. Cash and cash equivalents were approximately $159.3 million at quarter end. The results were furnished under Item 2.02 via press release dated November 5, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001517022-26-000083.

Written from the filing by Shamburg Markets. Figures are as reported by the company.